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trophic lateral sclerosis (ALS). CSF light chain neurofilaments (NfL) are increased in ALS.We exam-
ined whether CSF p/t-tau and NfL are related to ALS status in FTLD-TDP.
Methods: We compared CSF p/t-tau and NfL levels between patients with FTLD-TDP with ALS
(n 5 15), FTLD-TDP without ALS (n 5 17), FTLD-Tau (n 5 6), Alzheimer’s disease (AD;
n 5 25), and subjective memory complaints (SMC, n 5 24).
Results: Apart from FTLD-Tau, all groups differed significantly with increasing p/t-tau ratios from
FTLD-TDP with ALS to FTLD-TDP without ALS to AD and SMC. CSF NfL was very high in
FTLD-TDP with ALS followed by FTLD-TDP without ALS, AD, and SMC. Both biomarkers corre-
lated with survival.
Discussion: CSF p/t-tau ratio and NfL levels are strongly driven by ALS status. These markers,
therefore, appear to be more of prognostic than diagnostic significance.
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Frontotemporal dementia (FTD) is a clinical spectrum of
neurodegenerative disorders mainly affecting the frontal and
temporal lobes. When the disorder leads to severe personal-
ity and behavioral change, the resulting clinical syndrome is
termed the behavioral variant of FTD (bvFTD), whereas
both semantic dementia and progressive nonfluent aphasia
are the FTD language variants [1,2]. The clinical spectrum
of FTD is associated with several distinct pathologies
constituting the pathologic spectrum of frontotemporal
lobar degeneration (FTLD). FTLD with TAR DNA-
binding protein 43 inclusions (FTLD-TDP) and tau positiveimer’s Association. This is an open access article under the CC BY-NC-ND
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[3]. Clinico-pathologic correlations are not robust, except
when the underlying pathology of FTD is predicted by the
presence of an autosomal dominant mutation, where progra-
nulin gene mutations and C9orf72 repeat expansions give
rise to FTLD-TDP, and mutations in the tau gene are respon-
sible for FTLD-Tau [4,5]. In addition, FTD with
amyotrophic lateral sclerosis (ALS) is virtually always
associated with underlying FTLD-TDP [6].
In light of patient management and upcoming treatments,
the identification of FTLD pathologic subtypes is important
and cerebrospinal fluid (CSF) biomarker studies might aid in
this. Ideally, CSF biomarkers would also be able to predict
disease progression. So far, results of CSF biomarker studies
in FTD have been conflicting, probably partly due to the fact
that most studies included clinically diagnosed cases,
thereby introducing etiopathologic inaccuracy [7]. A study
in patients with known pathologies reported a reduced
CSF tau to amyloid b-42 ratio in FTLD compared with Alz-
heimer’s disease (AD) [8]. This finding was explained by the
biomarker abnormalities in AD because FTLD cases did not
differ from controls. More recently, a reduced CSF phospho-
tau181 to total tau ratio (p/t-tau ratio) has been suggested to
be useful to identify FTLD-TDP relative to FTLD-Tau [9].
In an independent patient group, it was confirmed that a
reduced CSF p/t-tau ratio distinguished FTLD-TDP from
FTLD-Tau, AD, and control subjects. This finding seems
contra-intuitive from a pathologic point of view because
tau pathology is not a hallmark of FTLD-TDP in contrast
to FTLD-Tau and AD. The results might, however, be ex-
plained in the context of increased CSF tau as a nonspecific
marker of neurodegeneration. In this light, another study ad-
dressing CSF markers of axonal degeneration in FTD path-
ologic subgroups found that CSF neurofilament light chain
(NfL) levels were strikingly increased in FTLD-TDP and
were correlated with disease severity and the degree of brain
atrophy [10].
CSF NfL levels have been found to be strongly increased
in ALS [11]. In line with this finding, the p/t-tau ratio has
been found to be reduced in ALS, although in one study
this was due to reduced p-tau levels, whereas another study
reported increased tau levels relative to CSF pTau [12,13].
Correlations with progression rate were found for CSF
NfL, and correlations with disease severity were found for
p/t-tau in ALS [13,14]. Based on the mentioned
information, we hypothesized that both CSF p/t-tau ratio
and NfL levels are associated with the rate of neurodegener-
ation in FTLD. Because FTDwith ALS has a more rapid dis-
ease course than FTD without ALS, we hypothesized that
their levels are related to ALS status in FTLD-TDP. In this
study, we set out to compare both CSF p/t-tau ratio and
NfL levels between patients with FTLD-TDP with ALS,
FTLD-TDP without ALS, FTLD-Tau, AD, and persons
with subjective memory complaints (SMC). Moreover, we
studied whether p/t-tau ratio and NfL were correlated with
survival.2. Methods
2.1. Patients
Patients were recruited from the Amsterdam Dementia
Cohort [15]. The study has been approved by the Medical
Ethical Review Board, and all patients or their representa-
tives gave written informed consent. In 15 FTLD-TDP with
ALS cases, the diagnosis had been confirmed by needle
electromyography based on the El Escorial criteria [16].
Neuropathologic confirmation of FTLD-TDP pathology
had taken place in one of these cases, whereas a C9orf72
repeat expansion was present in another of these cases.
FTLD-TDP cases without ALS (n 5 17) had been neuro-
pathologically confirmed in 11 of 17 cases; moreover, un-
derlying FTLD-TDP pathology was confirmed by the
presence of a progranulin gene mutation in 3 of 17 cases
and a C9orf72 repeat expansion in 5 of 17 cases. Two cases
that had been confirmed by autopsy turned out to be car-
riers of a C9orf72 repeat expansion. There were three neu-
ropathologically confirmed FTLD-Tau cases and three
patients carrying a tau gene mutation. Eleven AD cases
had been neuropathologically confirmed [17,18], whereas
the 19 cases with a clinical diagnosis of AD according to
the criteria of McKhann et al. [19] had a positive 11C Pitts-
burgh Compound B (PiB) positron emission tomography
(PET) [20]. Because clinical investigations in SMC are
normal, we used this subgroup as controls [21]. All sub-
jects in this group had CSF amyloid b-42 levels above
the cut off of 550 pg/mL. Disease duration was defined
as the time from reported symptom onset by a reliable
informant till time of diagnosis. To calculate survival, the
time of symptom onset was subtracted from the time of
death. Survival data became available via The Netherlands
Brain Bank or nursing homes.2.2. CSF examination
CSF was obtained by lumbar puncture between the L3/
L4 or L4/L5 intervertebral space, and 12 mL was collected
in polypropylene tubes. Within 1 hour, CSF samples were
centrifuged at 3000 rpm for 10 minutes at 4C. CSF was
aliquoted in polypropylene tubes of 0.5 or 1 mL, and stored
at 280C until analysis. For the determination of CSF
phospho-tau181 and tau levels, we used commercial
enzyme-linked immunosorbent assay (ELISAs; Innoge-
netics, Ghent, Belgium). The performance of these assays
is monitored with two internal quality control pools of sur-
plus CSF (high and low biomarker values). Interassay co-
efficients of variation (CV) (mean 6 standard deviation
[SD]) were 9.9 6 2.1% for Tau, and 9.1 6 1.8% for
pTau, as analyzed in a high and low pool from 13 consec-
utive pool preparations of two surplus CSF specimens (one
normal and one AD profile), used in total in 189–231 runs
[15]. We determined CSF levels of light chain NfL using
ELISAs (Uman) according to the manufacturer’s instruc-
tions. The CV of duplicates (n 5 149) was 1.5 6 1.1%.
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assay variation was 17.4% at 999 pg/mL and 15.9% at
50,789 pg/mL (sample diluted!50 in the assay) averaging
at 16.7% analyzed over five independent runs [22]. Lumbar
punctures were performed within 6 months of the time of
diagnosis. CSF p/t-tau ratio was calculated in 15 cases
with FTLD-TDP with ALS, 17 cases with FTLD-TDP
without ALS, six cases with FTLD-Tau, 25 cases with
AD, and 24 cases with SMC. CSF NfL levels could be
determined in 12 cases with FTLD-TDP with ALS, 14
cases with FTLD-TDP without ALS, four cases with
FTLD-Tau, 25 cases with AD, and 24 cases with SMC.
Of three cases with FTLD-TDP with ALS, three cases
with FTLD-TDP without ALS, and two cases with
FTLD-Tau insufficient CSF were stored to perform these
analyses.2.3. Statistical analysis
For statistical analysis, the statistical package SPSS 22.0
for Mac was used. Group comparisons were made using
analysis of variance followed by post-hoc Fisher Least
Significant Difference tests, Kruskal-Wallis followed by
post-hoc Mann-Whitney U tests, and chi-squared tests,
where appropriate. Nonparametric correlations were calcu-
lated using Spearman’s Rho. To determine diagnostic accu-
racy, receiver operating characteristic (ROC) curves were
drawn and areas under the curve (AUCs) were calculated.3. Results
Demographic data are presented in Table 1. Clinically, all
subjects with FTLD had bvFTD, except for two semantic de-
mentia cases that had pathologically confirmed FTLD-TDP.
These patients did not have ALS. Groups did not differ
regarding sex distribution and age. Reported disease dura-
tion at time of diagnosis was shorter in FTLD-TDP with
ALS than in FTLD-TDP without ALS and AD (P , .001,
P 5 .001, respectively).Table 1
Demographic data
FTLD-TDP
with ALS
n 5 15
FTLD-TDP
without ALS
n 5 17
FTLD-tau
n 5 6 A
Sex (M:F) 7:8 11:6 2:4 1
Mean age (SD) (y) 60.5 (6.0) 60.6 (7.4) 6
Mean disease duration (SD) (y) 1.6 (0.7) 5.7 (5.0)
Follow-up duration (mo) 3 (0–18) 19 (0–80) 10 (2–36)
Abbreviations: FTLD-TDP, frontotemporal lobar degeneration with TDP43 incl
subjective memory complaints; M, male; F, female; NS, not significant; SD, stand
NOTE. Values are displayed as mean (SD). Significant group differences wereIn 28 out of a total of 62 cases with dementia, the duration
from symptom onset until death was known. Mean survival
was 2.4 years (standard deviation 1.1) in seven patients with
FTLD-TDP with ALS, 8.0 years (SD 3.8) in 11 patients with
FTLD-TDP without ALS, and 8.0 years (SD 2.6) in nine pa-
tients with AD. One patient with pathologically proven
FTLD-Tau had a survival of 12 years.
Results of CSF biomarker analyses are displayed in
Fig. 1. Median CSF tau levels were 431 pg/mL (interquartile
range [IQR] 330) in FTLD-TDP with ALS, 353 pg/mL (IQR
109) in FTLD-TDP without ALS, 398 pg/mL (IQR 308) in
FTLD-Tau, 567 pg/mL (IQR 449) in AD, and 229 pg/mL
(IQR 112) in SMC. As expected, CSF tau levels were highest
in AD compared with both FTLD-TDP without ALS and
SMC (P 5 .001, P , .001, respectively). CSF tau levels,
however, were similar between AD, FTLD-TDP with
ALS, and FTLD-Tau (AD vs. FTLD-TDP with ALS
P 5 .14; AD vs. FTLD-Tau P 5 .10; and FTLD-TDP with
ALS vs. FTLD-Tau P 5 .59). In FTLD-TDP with ALS,
FTLD-TDP without ALS, and FTLD-Tau CSF Tau levels
were higher than in SMC (P , .001, P , .001, and
P 5 .01, respectively). CSF tau levels in FTLD-Tau without
ALS did not differ from controls.
Median CSF pTau181 levels were 38 pg/mL (IQR 13) in
FTLD-TDP with ALS, 38 pg/mL (IQR 17) in FTLD-TDP
without ALS, 52 pg/mL (IQR 36) in FTLD-Tau, 86 pg/mL
(IQR 56) in AD, and 45 pg/mL (IQR 20) in SMC. CSF
pTau181 levels were higher in AD compared with all FTLD
subgroups and SMC (AD vs. FTLD-TDP with ALS
P , .001, AD vs. FTLD-TDP without ALS P , .001, AD
vs. FTLD-Tau P 5 .02, and AD vs. SMC P , .001).
The median p/t-tau ratio, however, was lowest in FTLD-
TDP with ALS (0.08, IQR 0.02), followed by FTLD-TDP
without ALS (0.10, IQR 0.03), FTLD-tau (0.12, IQR
0.05), AD (0.14, IQR 0.03), and SMC (0.20, IQR 0.06).
The CSF p/t-tau ratio was significantly lower in FTLD-
TDP with ALS compared with all other groups (P , .001
vs. FTLD-TDP without ALS, AD and SMC, P 5 .002 vs.
FTLD-Tau). In FTLD-TDP without ALS, the CSF p/t-tau ra-
tio was significantly lower than in AD (P 5 .001) and SMCD n 5 25 SMC n 5 24 Significance
5:10 15:9 NS
3.0 (7.8) 62.2 (4.4) NS
3.6 (2.2) — FTLD-TDP with ALS versus FTLD-TDP
without ALS P , .001
FTLD-TDP with ALS versus FTD-Tau
P , .001
FTLD-TDP with ALS versus AD P 5 .01
25 (0–85) 12 (0–37)
usions; ALS, amyotrophic lateral sclerosis; AD, Alzheimer’s disease; SMC,
ard deviation; ANOVA, analysis of variance.
calculated using ANOVA followed by post hoc LSD t tests.
Fig. 1. Biomarker levels per diagnostic group. (A) CSF tau. (B) CSF pTau181, (C) CSF p/t-tau ratio. (D) CSF NfL. Significant group differences were calculated
using the Kruskal-Wallis test followed by the Mann-Whitney test. Abbreviations: CSF, cerebrospinal fluid; p/t-tau, p-Tau181 to total Tau ratio; NfL, neurofila-
ments. oOutliers of . 1.5 IQR. *Outliers of . 3 IQR.
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lower than in SMC (P , .001).
An opposite trend was seen in the levels of NfL where
median NfL was very high in FTLD-TDP with ALS
(20,509 pg/mL, IQR 10,622), compared with FTLD-TDP
without ALS (7712 pg/mL, IQR 4150), followed by
FTLD-tau (5462 pg/mL, IQR 5946), AD (2314 pg/mL,
IQR 1314), and SMC (1342 pg/mL, IQR 653). CSF NfL
levels were significantly higher in FTLD-TDP with ALS
compared with all other groups (P , .001 vs. FTLD-TDP
without ALS, AD, and SMC, P 5 .001 vs. FTLD-Tau).
CSF NfL levels were significantly higher in FTLD-TDP
without ALS compared with FTLD-Tau, AD, and SMC
(for all comparisons, P , .001). In AD, CSF NfL levels
were significantly higher than those in SMC (P , .001).
Fig. 2 presents CSF tau relative to CSF pTau levels per
disease group, showing that the reduced ratio was grossly
due to increased tau relative to normal or slightly increasedpTau. In the total group, CSF tau was significantly correlated
to CSF pTau (r 5 20.67, P , .001). The p/t-tau ratio was
negatively correlated with CSF NfL levels (r 5 20.69,
P , .001).
No significant correlations between any of the CSF bio-
markers and disease duration at time of diagnosis were
found. In the total patient group with known survival, CSF
p/t-tau ratio positively correlated with survival (r 5 0.60,
P 5 .001), whereas CSF NfL levels were negatively corre-
lated with survival (r520.62, P5 .01; Fig. 3). This finding
also holds true within the FTLD-TDP group (r 5 0.81,
P , .001 and r 5 20.71, P 5 .005, respectively).
CSF tau and pTau were significantly correlated with each
other (r 5 0.67, P , .001), but these individual biomarkers
were not correlated with survival (r 5 20.12, P 5 .54 for
CSF tau and r 5 0.28, P 5 .13 for CSF pTau).
ROC curves are displayed in Fig. 4. The diagnostic accu-
racy of CSF NfL for FTLD-TDP (with and without ALS)
Fig. 2. CSF tau relative to CSF pTau levels per diagnostic group. Abbrevi-
ations: CSF, cerebrospinal fluid; FTD-TDP, frontotemporal dementia with
TDP43 inclusions; ALS, amyotrophic lateral sclerosis; AD, Alzheimer’s
disease.
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(95% confidence interval [CI]: 0.98–1.0), which was even
higher than the AUC of 0.93 (95% CI: 0.87–0.98) for the
CSF p/t-tau ratio.4. Discussion
Our study confirms that a reduced CSF p/t-tau ratio is an
accurate biomarker for the total group of FTLD-TDP in the
differential diagnosis with AD and subjects without demen-
tia. The value of the CSF p/t-tau ratio in distinguishing
between FTLD-TDP and FTLD-Tau is less clear because
we clearly demonstrate that the presence of ALS has a major
effect on this ratio. We found a similar and strongly distinc-Fig. 3. Correlation of CSF p/t-ratio (A) and CSF NfL (B) with survival. Abbreviati
filaments.tive pattern for CSF NfL, with extremely high levels of CSF
NfL in FTLD-TDP with ALS, followed by FTLD-TDP
without ALS, and subsequently by FTLD-Tau, AD, and
SMC, respectively. P/t-tau ratio and NfL levels were nega-
tively correlated and both biomarkers were related to
survival.
Reduced CSF p/t-tau levels were found in ALS by Gross-
man et al. [13] where reduced CSF pTau levels were causing
this effect. The finding of decreased CSF p/t-tau ratio in ALS
was reproduced by another study; however, in this study,
CSF pTau was not reduced, but CSF Tau was increased
[12]. It was previously observed that a reduced CSF p/t-tau
ratio has a very high accuracy in detecting Creutzfeldt-
Jakob disease [23]. Because phosphorylation of tau occurs
mainly in AD and not so much in other neurodegenerative
disorders, the reduced p/t-tau ratio most likely reflects exten-
sive neuronal degeneration in actively degenerating diseases
leading to increased total CSF tau levels rather than a reduc-
tion in pTau levels. A similar mechanism might account for
the reduced p/t-tau ratio in FTLD-TDP with ALS, which has
a significantly shorter survival than FTD without ALS
[24,25]. Indeed, we found that FTLD-TDP with ALS cases
had the highest total tau levels relative to their p-tau levels.
We found no evidence for reduced CSF pTau levels in our
sample.
Our finding of increased CSF tau levels in FTLD sub-
groups is in agreement with some other studies that included
pathologically or genetically confirmed FTLD [10,26].
Other studies, however, found CSF tau levels in the normal
or low range in pathologically confirmed FTLD [8,27].
These conflicting results might be the consequence of
heterogeneity of the neurodegenerative process in FTLD.
Another possible explanation might be interassay variation
between different laboratories.
CSF NfL levels are increased in ALS, but also in multiple
sclerosis, and are considered as a dynamic marker for axonalons: CSF, cerebrospinal fluid; p/t-tau, p-Tau181 to total tau ratio; NfL, neuro-
Fig. 4. ROC curves of various biomarkers for FTLD-TDP versus AD and
SMC. Abbreviations: FTLD-TDP, frontotemporal lobar degeneration with
TDP43 inclusions; AD, Alzheimer’s disease; SMC, subjective memory
complaints.
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[11,28]. We previously reported on increased CSF NfL
levels in a pathologically undefined subgroup of FTD
patients [29]. More recently, elevated CSF NfL levels were
found in clinically diagnosed FTD cases, particularly in
those with evidence of underlying TDP43 pathology, and
correlations were found with the degree of frontotemporal
atrophy and disease severity [10,30]. A large study in 3356
subjects demonstrated that CSF NfL levels were highest in
FTD (of unspecified pathology) and vascular dementia,
compared with other types of dementia and healthy control
subjects [31]. Our findings stress that the degree of axonal
degeneration is apparently higher in FTLD-TDP than in
AD, and most prominent in FTLD-TDP with ALS.
Both CSF p/t-tau ratio and CSF NfL levels correlated
strongly to survival. Therefore, our study tentatively con-
firms the prognostic potential of these biomarkers. An earlier
study in AD cases revealing that the CSF p/t-tau ratio was
associated with the rate of cognitive decline hints into the
same direction [32]. Moreover, both in a large study
including various dementia types and in ALS, a negative
correlation between survival and CSF NfL levels has been
established [31,33].
Disease duration in FTD varies between 2 and 20 years
[34]. FTD with ALS is associated with the shortest disease
duration. On the other hand, disease courses with very
gradual decline have been described in a proportion of sub-
jects carrying the C9orf72 hexanucleotide expansion [35].
This heterogeneity in the rate of neurodegeneration appears
to be reflected in the variability of CSF p/t-tau ratio and NfL
levels in FTD.Patients with FTLD-TDP with ALS had much shorter
follow-up durations than the other patient groups, given
the severity of their clinical picture. Two of 15 patients
with FTLD-TDP with ALS developed ALS after an initial
diagnosis of bvFTD after 6 and 18 months, respectively.
Because nine of 17 patients with FTLD-TDP without ALS
had follow-up durations,18 months, theoretically these pa-
tients might still have developed ALS. This is very unlikely,
however, because FTD-ALS usually has a rapid disease
course.
Among the strengths of our study is the inclusion of cases
with known pathology by genetic and pathologic confirma-
tion and by the use of read-outs strongly suggestive of the
underlying pathology (electromyography for FTD-ALS
and PiB-PET for AD). By the inclusion of post-mortem veri-
fied and PiB-positive AD cases instead of CSF profile-based
cases, we avoided circular reasoning. Unfortunately, the
FTLD-Tau subgroup was relatively small, so no firm conclu-
sions can be drawn concerning this subgroup. The differ-
ences between FTLD-TDP and FTLD-Tau were strongly
driven by the presence of ALS because CSF p/t-tau ratio
and CSF NfL levels did not differ significantly between
FTLD-TDP without ALS and FTLD-Tau. Larger study
groups would be needed to confirm this. Because in the study
by Hu et al. [9] the FTLD-TDP group was taken together, it
remains possible that their finding of a decreased CSF p/t-tau
ratio in FTLD-TDP compared with FTLD-Tau is driven by
the inclusion of FTLD-TDP with ALS.
Our findings may have important implications for in vivo
pathologic subtyping in clinical FTD, which is highly rele-
vant in treatment development, and mainly address the
FTLD subgroup with TDP-43 positive pathology. Interest-
ingly, other in-vivo biomarkers of pathology have recently
been developed, such as tau-PET imaging and future studies
might clarify the relationship between CSF biomarkers, se-
lective tau imaging, and neuropathology [36]. Even though
tau positive inclusions are not a pathologic hallmark of
FTLD-TDP, the reduced p/t-tau ratio in this FTLD subtype
probably reflects the rate of neuronal degeneration. More-
over, the CSF p/t-tau ratio and CSF NfL levels have a high
potential for predicting survival in FTD, which is of utmost
importance for patient management and treatment moni-
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1. Systematic review: The authors reviewed the litera-
ture using PubMed. Although there are a limited
number of publications about the p-Tau181 to total
tau (p/t-tau) ratio in frontotemporal dementia, there
have been several publications about cerebrospinal
fluid (CSF) neurofilaments in various neurodegener-
ative and neurologic diseases and their correlation
with survival has been the subject of the study,
although not in the same context as our study. The
relevant citations are appropriately cited.
2. Interpretation: Our findings show that the decreased
CSF p/t-tau ratio as a biomarker for frontotemporal
dementia with TDP43 inclusions is driven by the
presence of amyotrophic lateral sclerosis. Both CSF
p/t-tau ratio and neurofilaments (NfL) levels corre-
late with survival.
3. Future directions: Our article warrants careful use of
biomarkers for frontotemporal dementia subtypes for
diagnostic purposes. Future research should point out
if CSF p/t-tau ratio and NfL are suitable biomarkers
for prognosis and monitoring of therapeutic effects.References
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